A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lenalidomide) with giving daratumumab as maintenance therapy, and they will look at which drug gives participants a better health-related quality of life during treatment. The researchers will measure participants' quality of life using various questionnaires. This study will help researchers find out whether this different approach of giving daratumumab as maintenance therapy is better, the same as, or worse than the usual approach.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Janssen Pharmaceuticals; Janssen Scientific Affairs, LLC
• Treatments: Daratumumab; Lenalidomide

Criteria

Inclusion Criteria:

• Patients with plasma cell myeloma treated with combination therapy with or without ASCT, who at the time of study enrollment have documented evidence of very good partial response (VGPR) or better according to International Myeloma Workshop Consensus Panel.

• Enrollment within 6 months from completion of initial combination therapy (with or without ASCT).

• Age ≥18 years.

• ECOG performance status ≤ 2 (see Appendix A).

• Subjects who have had ASCT may enroll following minimum 100-day washout per standard guidelines

• Patient must have adequate hematologic, renal, and hepatic function as defined by:

• Absolute neutrophil count ≥ 1.0K /μL (growth factor support is permissible)

• Platelets ≥ 50K/μL (transfusions are permissible)

• Hemoglobin ≥ 8 g/dL (transfusions are permissible)

• Creatinine clearance (CrCl) of greater than or equal to 40 mL/min. using the CKD-EPI formula (see Appendix C). If the CrCl based on the CKD-EPI formula is <40 mL/min, the patient will have a 24 hr urine collection to measure CrCl. The measured CrCl must also be ≥ 40 ml/min.

• Total bilirubin ≤ 2 mg/dL (exception: documented Gilbert's syndrome), AST (SGOT) and ALT (SGPT) ≤ 3 x ULN

• Patients must be able to take daily prophylactic anticoagulation medication, such as:

aspirin (81 or 325 mg) warfarin, low molecular weight heparin, or other medications as clinically indicated.

• Patients must be able to take prophylactic antiviral medication such as acyclovir or valacyclovir

• Patient must understand and voluntarily sign an informed consent form, with the understanding that the patient may withdraw consent at any time without prejudice to future medical care.

Additional inclusion criteria for patients randomized to arm A:

• Study participants must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of the REMS® program.

• Females of childbearing potential* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS®) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide, while taking lenalidomide, and for at least 4 weeks after stopping lenalidomide. (If patient is already on induction lenalidomide for the month prior and have the standard 7 days off before they start maintenance then a single pregnancy test within 24 hours is acceptable. If a patient has been off lenalidomide for >14 days prior to initiating maintenance then they will require 2 urine tests as described above.)

• A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).

• Females of childbearing potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.

• Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy. See Appendix B: Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.

Additional inclusion criteria for patients randomized to arm B:

• Females of reproductive potential must agree to use an effective method of birth control during treatment and for at least 3 months after cessation of daratumumab.

• Males who are sexually active with a female of reproductive potential must agree to use an effective method of birth control during treatment and for at least 3 months after cessation of daratumumab.

• Subjects agree to not donate eggs/sperm for 3 months following cessation of daratumumab.

Exclusion Criteria:

• Patients with progressive or refractory plasma cell myeloma, as defined by International Myeloma Workshop Consensus Panel criteria.

• History of disease refractory to lenalidomide or daratumumab, as defined by the IMWG as failure to achieve minimal response or development of progressive disease while on therapy.

• Multiple myeloma patients who have received prior anti myeloma therapy for smoldering myeloma

• Patients who are receiving any other investigational agents with the intent to treat myeloma. Permitted concurrent therapies include:

• Bisphosphonates/RANK ligand inhibitors (denosumab)

• Plasma cell leukemia

• Pregnant or breastfeeding females. Because there is a potential risk for adverse events to nursing infants secondary to treatment of the mother with lenalidomide, lactating females must agree not to breastfeed while taking lenalidomide.

• Risk for adverse events to nursing infants secondary to treatment of the mother with daratumumab is unknown, as such lactating females must agree not to breastfeed while on daratumumab.

• Patient has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal).

• Patient has known moderate or severe persistent asthma, within the last 2 years, or currently has uncontrolled asthma of any classification (refer to Appendix D). (Subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.)

• Uncontrolled hypertension or diabetes

• Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.

• Hepatitis C PCR positive excluded (If antibody positive and PCR negative they will be eligible but must have PCR testing every 3-6 months for 3 years; If treated must have a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).

• Diagnosed or treated for another malignancy within 3 years prior to study enrollment, with the exception of complete resection of non-melanoma skin cancer, or an in-situ malignancy.

• Previous diagnosis of another malignancy with any evidence of residual or active disease.

• Uncontrolled or detectable HIV viral load excluded. (Patients seropositive for the human immunodeficiency virus (HIV), and/or those who are taking antiretroviral treatment for HIV/AIDS with undetectable viral load will be eligible. Patients must have PCR testing every 3-6 months for 3 years and be compliant with antiretroviral treatment.)

• Prior organ transplant requiring immunosuppressive therapy

• Prior allogeneic stem cell transplant

• Patients requiring continuous, systemic immunosuppressive therapy

• Patients with myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled cardiac arrhythmias, or electrocardiographic evidence of acute ischemia

• Patients with conditions that would prevent absorption of the study drug

• Uncontrolled intercurrent illness including but not limited to uncontrolled infection or psychiatric illness/social situations that would compromise compliance with study requirements

• Unresolved prior treatment related AE ≥ grade 2 except for alopecia and neuropathy

• Neuropathy ≥ Grade 3 at baseline

• Contraindication to required concomitant anticoagulation or antiviral prophylaxis

• Major surgery within 1 month prior to enrollment

• Patients who were previously exposed and who developed severe adverse events, hypersensitivity or desquamating rash to either thalidomide or lenalidomide

• Patients who speak a language that does not have an EORTC QLQ-C30, MY20 or PRO-CTCAE version translated into their language (Available languages include Chinese, Czech, Danish, Dutch, French, German, Greek, Hugarian, Italian, Japanese, Korean, Malay, Polish, Protugese, Romanian, Russian, Spanish, Turkish, Ukranian).